No Influence of the MDR-1 C3435T Polymorphism or a CYP3A4 Promoter Polymorphism (CYP3A4-V Allele) on Dose-adjusted Cyclosporin A Trough …
N von Ahsen, M Richter, C Grupp, B Ringe… - Clinical …, 2001 - academic.oup.com
Background: A substantial proportion of the variability in the absorption and clearance of
cyclosporin A (CsA) after oral administration has been attributed to variability in liver …
cyclosporin A (CsA) after oral administration has been attributed to variability in liver …
Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients
A Santoro, CR Felipe, H Tedesco-Silva… - …, 2011 - Future Medicine
Aim: Polymorphisms in the CYP3A5 and ABCB1 genes have been investigated as
modulators of the pharmacokinetics and clinical effects of cyclosporine (CSA) and tacrolimus …
modulators of the pharmacokinetics and clinical effects of cyclosporine (CSA) and tacrolimus …
Association of genetic variants in CYP3A4, CYP3A5, CYP2C8, and CYP2C19 with tacrolimus pharmacokinetics in renal transplant recipients
Z Wang, M Zheng, H Yang, Z Han, J Tao… - Current Drug …, 2019 - ingentaconnect.com
Background: Our study aimed to investigate the pharmacogenetics of cytochrome P3A4
(CYP3A4), CYP3A5, CYP2C8, and CYP2C19 and their influence on TAC Pharmacokinetics …
(CYP3A4), CYP3A5, CYP2C8, and CYP2C19 and their influence on TAC Pharmacokinetics …
Frequencies of CYP3A5*1/*3 Variants in a Moroccan Population and Effect on Tacrolimus Daily Dose Requirements in Renal Transplant Patients
M Elmachad, D Elkabbaj, F Elkerch… - Genetic Testing and …, 2012 - liebertpub.com
The cytochromes P450 are a superfamily of oxidative enzymes, which are implicated in the
metabolism of a large number of endogenous substances as well as exogenous chemicals …
metabolism of a large number of endogenous substances as well as exogenous chemicals …
The new CYP3A4 intron 6 C> T polymorphism (CYP3A4* 22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine …
L Elens, R Bouamar, DA Hesselink… - Pharmacogenetics …, 2012 - journals.lww.com
Objective Cyclosporine A (CsA) is a substrate of cytochrome P450 3A4 (CYP3A4). Recently,
a newly discovered intron 6 single-nucleotide polymorphism in CYP3A4 (rs35599367 C> T) …
a newly discovered intron 6 single-nucleotide polymorphism in CYP3A4 (rs35599367 C> T) …
Polymorphisms in CYP3A5* 3 and MDR1, and haplotype modulate response to plasma levels of tacrolimus in Chinese renal transplant patients.
P Wu, X Ni, M Wang, X Xu, G Luo… - Annals of transplantation, 2011 - europepmc.org
Background The purpose of this study was to investigate the effects of polymorphisms in
CYP3A5* 3, CYP3AP1, and MDR1, and of haplotype, on plasma levels of tacrolimus in …
CYP3A5* 3, CYP3AP1, and MDR1, and of haplotype, on plasma levels of tacrolimus in …
Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients12
E Thervet, D Anglicheau, B King, MH Schlageter… - …, 2003 - journals.lww.com
Background. Tacrolimus pharmacokinetic characteristics vary greatly among individuals.
Tacrolimus is a substrate of cytochrome P450 (CYP), of subfamily CYP3A. CYP3A activity is …
Tacrolimus is a substrate of cytochrome P450 (CYP), of subfamily CYP3A. CYP3A activity is …
Effect of CYP3A4* 22, CYP3A5* 3 and POR* 28 genetic polymorphisms on calcineurin inhibitors dose requirements in early phase renal transplant patients
AHIM Ebid, DA Ismail, NM Lotfy… - Pharmacogenetics …, 2024 - journals.lww.com
Objective This study aimed to investigate the combined effect of CYP3A5* 3, CYP3A4* 22,
and POR* 28 genetic polymorphisms on tacrolimus and cyclosporine dose requirements …
and POR* 28 genetic polymorphisms on tacrolimus and cyclosporine dose requirements …
Prevalence of CYP3A5 Genomic Variances and Their Impact on Tacrolimus Dosing Requirements among Kidney Transplant Recipients in Eastern North Carolina
AQ Maldonado, T Asempa, S Hudson… - … : The Journal of …, 2017 - Wiley Online Library
To assess the prevalence of CYP 3A5 genomic variances and their impact on tacrolimus
(TAC) dosing requirements among kidney transplant recipients in eastern North Carolina …
(TAC) dosing requirements among kidney transplant recipients in eastern North Carolina …
CYP3A5 and CYP3A4 but not MDR1 Single‐nucleotide Polymorphisms Determine Long‐term Tacrolimus Disposition and Drug‐related Nephrotoxicity in Renal …
DRJ Kuypers, H de Jonge, M Naesens… - Clinical …, 2007 - Wiley Online Library
The impact of CYP3A and MDR1 gene single‐nucleotide polymorphisms on long‐term
tacrolimus disposition and drug‐related toxicity has not been assessed. A study was …
tacrolimus disposition and drug‐related toxicity has not been assessed. A study was …